Show results for
Refine by
Clinical Trial Equipment Supplied In Usa Utah
5 equipment items found
by:Sumitomo Pharma Oncology, Inc. based inCambridge, MASSACHUSETTS (USA)
TP-3654 is an oral investigational inhibitor of PIM kinases, which has potential antitumor and anti-fibrotic effects through multiple pathways, including induction of ...
by:Sumitomo Pharma Oncology, Inc. based inCambridge, MASSACHUSETTS (USA)
TP-1287 is an investigational oral CDK9 inhibitor that has shown favorable oral bioavailability in preclinical models. TP-1287 is enzymatically cleaved, yielding the active moiety, a potent inhibitor of CDK9.35 Inhibiting CDK9 is thought to downregulate the transcription of target genes, including MCL-1, reducing leukemic blast viability in MCL-1–dependent hematologic malignancies, and ...
by:Sumitomo Pharma Oncology, Inc. based inCambridge, MASSACHUSETTS (USA)
Ombipepimut-S Emulsion (DSP-7888) is an investigational immunotherapeutic cancer vaccine containing 2 peptides that induce WT1-specific cytotoxic T lymphocytes (WT1-CTLs) and helper T cells to attack WT1-expressing cancerous cells found in various types of hematologic malignancies and solid tumors.1,2 Researchers have identified that adding helper T-cell–inducing peptides improved ...
by:Sumitomo Pharma Oncology, Inc. based inCambridge, MASSACHUSETTS (USA)
DSP-0509 is an investigational Toll-like receptor (TLR) 7 agonist, which is hypothesized to induce cytokine production, activate cytotoxic T lymphocytes, and sustain immune-mediated antitumor ...
by:Alucent Biomedical Inc. based inSalt Lake City,, UTAH (USA)
The Alucent NVS Vessel Restoration System is designed to create a natural, stent-like scaffold using the body’s own tissue and processes. An all-in-one, integrated procedural system, Alucent NVS combines standard angioplasty techniques with a small molecule drug that when photoactivated, promotes extracellular matrix protein linking inside the vessel ...